ISRCTN11503604进行中（未招募）2 期
Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Written informed consent prior to admission to this study
- •2. Age =16 years. No upper age limit
- •3. ECOG performance status 0 or 1
- •4. Histologically proven pancreatic ductal adenocarcinoma (PDAC) as part of the Precision-Panc Master Protocol, or for patients who have gone exploratory laparotomy and found to have locally advanced disease
- •5. Locally advanced disease which is measurable according to the Response Evaluation Criteria in Solid Tumours (RECIST v1.1)
- •6. CT chest abdomen and pelvis as well as PET-CT within 28 days of day 1 of treatment (MRI Liver only if indeterminate liver lesions) to confirm absence of metastatic disease.
- •7. Received no prior systemic therapy for pancreatic cancer
- •8. Adequate haematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment:
- •8.1. Absolute Neutrophil Count =1.5 x 10^9/l (without granulocyte colony-stimulating factor support within 2 weeks prior to the first study treatment)
- •8.2. Platelet count =100 x 10^9/l (without transfusion within 2 weeks prior to the first study treatment)
- •8.3. Haemoglobin =10 g/dl (transfusion permitted to establish target haemoglobin levels prior to the first study treatment)
- •8.4. Calculated creatinine clearance (e.g. Cockcroft-Gault) = 50 ml/min
- •8.5. Bilirubin level =1.5 ULN (patients with known Gilbert disease who have bilirubin levels =3 x ULN may be enrolled). Patients must be able to undergo biliary stenting if required before or, if required, during the trial
- •8.6. AST or ALT <2.5 x ULN
- •8.7. Alkaline phosphatase (ALP) <2.5 x ULN
- •8.8. INR and aPTT =1.5 x ULN this applies only to patients who are not receiving therapeutic anticoagulation patients receiving therapeutic anticoagulation should be on a stable dose
- •9. Female patients of child-bearing potential are eligible, provided they have a negative serum pregnancy test within 7 days prior to the first dose of study treatment, preferably as close to the first dose as possible. All patients with reproductive potential must agree to use a medically acceptable method of contraception throughout the treatment period and for 1 month after discontinuation of ATRA and / or gemcitabine/nab-paclitaxel (whichever is the latest) and for 6 months after discontinuation for male patients. Acceptable methods of contraception include IUD, oral contraceptive, sub-dermal implant and double barrier (condom with a contraceptive sponge or contraceptive pessary). Micro-dosed progesterone preparations (mini-pill”) are an inadequate method of contraception during treatment with ATRA. If patients are taking this pill they should be instructed to stop and another form of contraceptive should be prescribed instead
- •10. Able to follow protocol requirements as assessed by the Principal Investigator
排除标准
- •1. Patient has known metastases
- •2. Patient has experienced a significant reduction in performance status between the screening/ baseline visit and within 72 hours prior to commencement of treatment as per trial protocol, and as per the Investigator’s assessment
- •3. Patients with pre-existing sensory neuropathy >grade 1
- •4. History of other malignancies (except cured basal or squamous cell carcinoma, superficial bladder cancer, prostate cancer in active surveillance, or carcinoma in situ of the cervix) unless documented free of cancer for =2 years
- •5. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
- •6. Patient has known active, uncontrolled HIV, or active, uncontrolled hepatitis B or C infection. Patients with undetectable viral load are eligible
- •7. Patient has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study
- •8. Patient has a history of allergy (including soya bean or peanut allergies) or hypersensitivity to any of the study drugs or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the products or comparator SmPC or Prescribing Information
- •9. History of connective tissue disorders (e.g., lupus, scleroderma, arteritis nodosa)
- •10. Patient with a history of interstitial lung disease, history of slowly progressive dyspnoea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
- •11. Patient with high cardiovascular risk, including, but not limited to, recent coronary stenting or myocardial infarction in the past year. A high cardiovascular risk is defined as person having recent (within last 12 months) coronary stenting or myocardial infarction or unstable angina which in the opinion of Principal Investigator, with or without a cardiologist opinion, is deemed to have an absolute risk for cardiovascular death of = 5% over next 10 years. (ESC/ESH guidelines)
- •12. History of Peripheral Artery Disease (e.g., claudication, Leo-Buerger's disease)
- •13. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity
- •14. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug =30 days prior to study entry depending on the half-life of the investigational drug and/or guidance issued by the IMP manufacturer. Please contact the STARPAC2 coordinating team for further information
- •15. Patient is taking any prohibited concurrent medication, including vitamin A supplements, and is unwilling to stop use prior to and during the trial
- •16. Patient is pregnant, planning to become pregnant or breast feeding
- •17. Patient has received a live vaccine within four weeks prior to receiving their first dose of study treatment
- •18. Patient is unwilling or unable to comply with study procedures, as assessed by the Principal Investigat
研究者
相似试验
进行中（未招募）
1 期
Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancerEUCTR2019-004231-23-GBQueen Mary University of London170
已完成
不适用
Phase II randomized clinical trial for the purpose of examining the protective efficacy of the non-alcoholic fatty liver development by pancrelipase preparation being given for pancreatic cancer patients who underwent pancreaticoduodenectomy or total pancreatectomy.To assume the decreased rate of post-operative non-alcoholic fatty liver incidence in pancreatic cancer patients with the prophylactic administration of the pancrelipase preparation.JPRN-UMIN000019817Department of Surgery, Kansai Medical University80
进行中（未招募）
不适用
A randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastomaEUCTR2011-000900-16-BEZ BRUSSE
进行中（未招募）
1 期
A trial to determine the effectiveness of targeted radiotherapy in stem cell transplantation.MedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple myelomaEUCTR2006-003424-12-GBniversity Hospital Southampton NHS Foundation Trust90
已完成
2 期
Targeted radiotherapy delivered by an yttrium-90 radio-labelled Anti-CD66 monoclonal antibody with high dose melphalan compared to melphalan alone, prior to autologous stem cell transplantation for multiple myelomaMultiple myelomaCancerISRCTN11933044Southampton University Hospitals NHS Trust (UK)25